Skip to Content
Uncategorized

The FDA Is Cracking Down on Sketchy Stem Cell Clinics

August 29, 2017

The offer of some clinics to treat all kinds of illness using injections of stem cells may soon come to an end. For several years, many businesses have offered the approach—which often takes stem cells from one tissue and places them in an unrelated organ—to treat everything  from autism to cerebral palsy. But as we’ve reported in the past, there’s little evidence it works, and the procedures can even prove harmful. And while patients used to travel overseas for the treatment, centers offering the technique have recently begun to proliferate across America, too.

Now, though, the FDA is clamping down. It's announced that it raided the labs of one clinic, called StemImmune, in order to seize vials of a live virus that the company was mixing with stem cells and injecting into people. It's written a letter to U.S. Stem Cell Inc. in Florida, warning it that its injections of stem cells into spinal cords could put patients at risk. And in a statement from FDA commissioner Scott Gottlieb, the administration says that it plans to introduce new policies to stamp out "deceptive, and sometimes corrupt, assurances to patients based on unproven and, in some cases, dangerously dubious products."

Deep Dive

Uncategorized

Capitalizing on machine learning with collaborative, structured enterprise tooling teams

Machine learning advances require an evolution of processes, tooling, and operations.

The race to destroy PFAS, the forever chemicals 

Scientists are showing these damaging compounds can be beat.

How scientists are being squeezed to take sides in the conflict between Israel and Palestine

Tensions over the war are flaring on social media—with real-life ramifications.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.